← Back to Search

[F-18]MeFAMP PET for Brain Tumors

Phase < 1
Waitlist Available
Led By Jonathan McConathy, MD, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
18 years of age or older at the time of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from injection to 45 minutes, 2 hours, and 4 hours after pet agent administration.
Awards & highlights

Summary

This trial will test if a new imaging tech is safe and effective for imaging brain tumors. It will also explore if it can accurately distinguish tumors from radiation effects.

Who is the study for?
This trial is for adults over 18 with a life expectancy of more than 12 weeks. It includes healthy volunteers, those with high-grade glioma after radiation, and patients with brain metastases from other tumors. Women able to have children must test negative for pregnancy.
What is being tested?
[F-18]MeFAMP PET imaging is being tested to see if it's safe and how well it can show primary and metastatic brain tumors. The study has three parts: one for healthy people, one for glioma patients, and another for those with brain metastases.
What are the potential side effects?
Since this is the first time [F-18]MeFAMP PET is used in humans, part of the study aims to establish its safety profile. Potential side effects are not detailed but will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from injection to 45 minutes, 2 hours, and 4 hours after pet agent administration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from injection to 45 minutes, 2 hours, and 4 hours after pet agent administration. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Human dosimetry for [F-18]MeFAMP.
Safety of [F-18]MeFAMP

Trial Design

3Treatment groups
Experimental Treatment
Group I: High Grade Glioma (cohort 2)Experimental Treatment1 Intervention
Recurrent high grade glioma after radiation therapy
Group II: Healthy Volunteers (cohort 1)Experimental Treatment1 Intervention
Whole Body Dosimetry for healthy volunteers
Group III: Brain Metastasis (cohort 3)Experimental Treatment1 Intervention
Brain metastases from extra-cranial solid tumors before and after radiation therapy

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,621 Previous Clinical Trials
2,290,950 Total Patients Enrolled
Jonathan McConathy, MD, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
5 Previous Clinical Trials
146 Total Patients Enrolled
~19 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top